Skip to Content

INCY 15 (Jakafi 15 mg)

Generic Name: ruxolitinib

Pill with imprint INCY 15 is White, Elliptical / Oval and has been identified as Jakafi 15 mg. It is supplied by Incyte Corporation.

Jakafi is used in the treatment of myelofibrosis; polycythemia vera; graft-versus-host disease; myeloproliferative disorders and belongs to the drug class multikinase inhibitors. Risk cannot be ruled out during pregnancy. Jakafi 15 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for INCY 15

Jakafi

Generic Name
ruxolitinib
Imprint
INCY 15
Strength
15 mg
Color
White
Size
15.00 mm
Shape
Elliptical / Oval
Availability
Prescription only
Drug Class
Multikinase inhibitors
Pregnancy Category
C - Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Incyte Corporation
National Drug Code (NDC)
50881-0015
Inactive Ingredients
microcrystalline cellulose, lactose monohydrate, silicon dioxide, hydroxypropyl cellulose (type e), povidone, sodium starch glycolate type A potato, magnesium stearate

Note: Inactive ingredients may vary.

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.